Reuters logo
BRIEF-ExpreS2ion Biotech Holding: successful completion of phase I
July 5, 2017 / 10:30 AM / 4 months ago

BRIEF-ExpreS2ion Biotech Holding: successful completion of phase I

July 5 (Reuters) - EXPRES2ION BIOTECH HOLDING AB

* SUCCESSFUL COMPLETION OF PHASE I AND INITIATION OF PHASE IIA CLINICAL TRIAL OF A UNIVERSAL MALARIA VACCINE PRODUCED IN EXPRES2

* RESULTS EXCPECTED IN LATE 2018

* PHASE I STUDY ASSESSED SAFETY OF VACCINE AND IMMUNE RESPONSE, AS WELL AS OPTIMAL DOSING REGIMEN OF VACCINE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below